Data supports further clinical evaluation of brincidofovir for the treatment and prevention of BK virus
Chimerix (NASDAQ:CMRX) today announced data from two preclinical studies which assessed the in vivo antiviral activity of brincidofovir (BCV) against polyomavirus. These studies are part of the company’s ongoing effort to develop antivirals in high unmet medical need areas, including hematopoietic cell transplant (HCT) and solid organ transplant patient populations. These data will be presented at the American Society of Nephrology’s Kidney Week 2018, held October 23-28 in San Diego, CA.
Polyomaviruses are a family of small DNA viruses that persistently infect their hosts for life. BK virus (BKV) is a human polyomavirus that presents a significant risk to those who are immunocompromised and immunosuppressed. Approximately 15 percent of kidney transplant recipients develop BKV in the first year following transplant, and infection can lead to kidney damage and organ loss. Current treatment for BKV is a reduction of immunosuppression, which can result in organ rejection.
“Almost 6,000 kidney transplant recipients in the United States and Europe develop BK infection annually and are at risk of losing their new kidney. The prevention and treatment of BK virus represents a significant unmet need,” said Garrett Nichols, MD, MS, Chief Medical Officer of Chimerix. “These preclinical studies of brincidofovir provide further evidence of its antiviral activity against polyomavirus.”
These two studies evaluated BCV’s effect against MuPyV, a mouse polyomavirus closely related to the human BK virus. In these studies, mice with MuPyV were treated with BCV either 24 hours after being infected or prophylactically for a full week prior to infection. Data from the two studies show that BCV demonstrated significant antiviral activity against MuPyV and showed no safety signals across BCV doses administered. In mice treated after infection with MuPyV, BCV delivered via intraperitoneal injection once daily, twice weekly or once weekly reduced kidney viral loads by 100-fold relative to those that received placebo, while administration prophylactically showed that BCV 20 mg/kg or higher decreased viral load in the kidney by approximately 10-fold.
“These animal mouse studies build on our growing understanding of brincidofovir’s potential to prevent or treat BK virus infection in recipients of kidney transplants or after a stem cell transplant,” said Dr. Nichols. “A previous Phase 2 study in stem cell transplant recipients showed improved kidney function and reduced renal impairment in brincidofovir-treated patients, suggesting its potential activity against BK virus; the new in vivo data confirm what was seen in past in vitro studies, showing that brincidofovir is active against polyomaviruses. With results from these studies in hand, we look forward to progressing a clinical study of brincidofovir against BK virus.”
Chimerix presentations during the Pharmacology Poster Session on October 27, 2018 at 10:00 a.m. PDT (1:00 p.m. EDT):
- Activity of Brincidofovir (BCV) against Murine Polyoma Virus (MuPyV) in a mouse infection model [SA-PO641]
- Brincidofovir (BCV) Demonstrates Antiviral Activity against Murine Polyoma Virus (MuPyV) in a mouse model of acute infection [SA-PO642]
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.